DAREON-9: interim findings of obrixtamig and topotecan in pre-treated SCLC скачать в хорошем качестве

DAREON-9: interim findings of obrixtamig and topotecan in pre-treated SCLC

Martin Wermke, MD, TU Dresden University of Technology, Dresden, Germany, comments on interim findings from the Phase Ib DAREON-9 trial (NCT05990738) of obrixtamig with topotecan in patients with advanced small cell lung cancer (SCLC) previously treated with platinum-based therapy. The combination was generally well tolerated, with manageable adverse events and no unexpected safety signals. Preliminary efficacy signals were promising, with a high rate of tumor response and disease control observed. These results support continued investigation of this bispecific T-cell engager strategy in this setting. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.